Zacks Research Issues Optimistic Outlook for GSK Earnings

GSK PLC Sponsored ADR (NYSE:GSK - Free Report) - Stock analysts at Zacks Research increased their Q2 2026 EPS estimates for GSK in a research note issued to investors on Wednesday, July 23rd. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings of $1.15 per share for the quarter, up from their prior estimate of $1.13. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's Q4 2026 earnings at $1.11 EPS, FY2026 earnings at $4.78 EPS and FY2027 earnings at $4.90 EPS.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter in the previous year, the firm posted $0.43 earnings per share. GSK's revenue was up 2.1% compared to the same quarter last year.

Several other brokerages have also issued reports on GSK. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Saturday. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Stock Performance

GSK stock traded down $0.28 on Thursday, reaching $37.95. 4,009,306 shares of the company were exchanged, compared to its average volume of 5,818,628. GSK has a 12 month low of $31.72 and a 12 month high of $44.67. The stock's fifty day moving average price is $39.03 and its 200 day moving average price is $37.50. The firm has a market capitalization of $77.70 billion, a PE ratio of 19.56, a PEG ratio of 1.56 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Stockholders of record on Friday, May 16th were paid a $0.4216 dividend. This represents a $1.69 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend was Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 88.14%.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently made changes to their positions in GSK. HHM Wealth Advisors LLC lifted its position in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 460 shares in the last quarter. Costello Asset Management INC bought a new stake in GSK during the 1st quarter worth about $31,000. SOA Wealth Advisors LLC. grew its holdings in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 605 shares during the last quarter. Richardson Financial Services Inc. grew its holdings in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the last quarter. Finally, Olde Wealth Management LLC bought a new stake in GSK during the 1st quarter worth about $36,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.